ARTICLE | Company News

Azur Pharma, BioSante sales and marketing update

December 21, 2009 8:00 AM UTC

Azur will pay $1 million to BioSante in exchange for reducing the royalties that Azur owes BioSante on U.S. sales of Elestrin estradiol by an undisclosed amount. Azur has an option to pay an addition...